Pediatric drug development faces many difficulties. Traditionally, pediatric drug doses are
simply calculated linearly based on the body weight, age, and body surface area of adults …

The paradigm of pediatric drug development has been evolving in a “carrot-and-stick”-based
tactic to address population-specific issues. However, the off-label prescription of adult …

模型引导的精准用药(MIPD) 是通过数学建模与模拟技术, 将患者, 药物和疾病等相关信息进行
整合, 为患者精准用药提供依据. 相较于经验用药, MIPD 是一种基于患者生理, 病理, 遗传 …

Abstract Background and Objective More than half of all drugs are still prescribed off-label to
children. Pharmacokinetic (PK) data are needed to support off-label dosing, however for …

In the past decade, only a small number of papers have elaborated on the application of
physiologically based pharmacokinetic (PBPK) modeling across different areas. In this …

Maternal and pediatric populations have historically been considered “therapeutic orphans”
due to their limited inclusion in clinical trials. Physiologic changes during pregnancy and …

Buprenorphine plays a crucial role in the therapeutic management of pain in adults,
adolescents and pediatric subpopulations. However, only few pharmacokinetic studies of …

Background The combination of polymyxins, meropenem, and sulbactam demonstrated
efficacy against multi-drug-resistant bacillus Acinetobacter baumannii. These three …

Physiologically based pharmacokinetic (PBPK) models have been proposed as a tool for
more accurate individual pharmacokinetic (PK) predictions and model‐informed precision …

Constant technological advancement enabled the production of therapeutic monoclonal
antibodies (mAbs) and will continue to contribute to their rapid expansion. Compared to …